Rare coding variation and risk for myocardial infarction
罕见的编码变异和心肌梗塞的风险
基本信息
- 批准号:8607417
- 负责人:
- 金额:$ 13.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-08-15 至 2017-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAllelesBioinformaticsCandidate Disease GeneCardiovascular DiseasesCardiovascular systemCase-Control StudiesCause of DeathClinicalCodeCommunication ResearchComplexComputing MethodologiesDNA SequenceDataDiseaseDisease AssociationDoctor of PhilosophyElderlyEnvironmentFellowshipFoundationsFrequenciesFundingGene FrequencyGeneral HospitalsGenesGeneticGenetic RiskGenetic VariationGenomeGenomicsGenotypeGoalsGroupingGuidelinesHospitalsHuman GeneticsIndividualInstitutesInternal MedicineInterventionInvestigationK-Series Research Career ProgramsKnowledgeLarge-Scale SequencingLeadMassachusettsMedicineMentorsMethodsMinorModelingMyocardial InfarctionOpen Reading FramesPathway interactionsPerformancePhenotypePhysiciansPlayPopulationPopulation GeneticsPositioning AttributePreventionPrincipal InvestigatorResearchResearch EthicsResearch PersonnelResidenciesRiskRisk FactorsRoleSamplingScientistSolidStratificationTechnologyTestingTrainingUnited StatesVariantWomanWorkbasecareer developmentcase controlclinical riskdesigndisorder riskearly onsetexomeexome sequencingexperiencegenetic associationgenetic variantgenome wide association studyhigh riskimprovedlifetime risknext generationnovelnovel strategiesnovel therapeuticspopulation basedskillssuccess
项目摘要
DESCRIPTION (provided by applicant): Myocardial infarction (MI) is the leading cause of death in the United States and is heritable. Large studies focusing on common genetic variation have now identified over 30 loci associated with risk for MI. Despite this success, these common variants explain only a small proportion of the genetic basis of MI. Population genetics and candidate gene studies support the hypothesis that less common genetic variation plays a significant role in complex disorders such as MI. In this proposal, we outline several methods to explore the role of rare genetic variation in risk for MI. Using a set of rare (minor allele frequecy < 5%) coding variants identified through whole exome sequencing (i.e. all protein coding regions of the genome), we will test the hypotheses that rare variants contribute to MI risk both individually and collectively and further that this knowledge can improve population-based risk stratification. To test these hypotheses, we propose the following specific aims: in Aim 1, we will
genotype exome variants in a well-powered case/control study to identify rare variants that individually contribute to risk of MI; in Aim 2, we will develop novel computational methods for rare variant analysis to identify rare variants collectively associated with MI; and in Aim 3, we will develop a rare variant method for population-based MI risk stratification. In addition to elucidating the role of rare coding variation in risk for MI, this five-year proposal outlines a comprehensive strategy for the principal investigator's career development in academic cardiovascular medicine. This strategy logically builds on the principal investigator's previous research experience and clinical training. After obtaining a Ph.D. in Bioinformatics, the principal
investigator completed residency training in Internal Medicine and is currently finishing fellowship training in Cardiovascular Disease. This proposal now focuses on expanding his scientific skills by attaining additional knowledge and practical research experience in human genetics and genomics, statistical genetics, and risk modeling. The career development goals will be achieved through a multi-faceted approach involving mentoring by Dr. Sekar Kathiresan (human genetics and genomics) and Dr. Shamil Sunyaev (statistical genetics, risk modeling), didactic coursework, scientific investigation, and training in scientific communication and research ethics. This work will take place in a unique training environment comprised of complementary experiences at Massachusetts General Hospital, Brigham and Women's Hospital, and the Broad Institute. Successful completion of this career development award will result in a better understanding of the genetic basis for MI, result in the principal investigator' transition to an independent physician-scientist, and provide a solid foundation from which he will apply for RO1-level funding.
描述(由申请人提供):心肌梗死(MI)是美国死亡的主要原因,并且是遗传性的。目前,针对常见遗传变异的大型研究已经确定了30多个与心肌梗死风险相关的位点。尽管取得了成功,但这些常见变异只能解释心肌梗死遗传基础的一小部分。群体遗传学和候选基因研究支持这样的假设,即不常见的遗传变异在心肌梗死等复杂疾病中起着重要作用。我们概述了几种方法来探索罕见遗传变异在心肌梗死风险中的作用。使用一组通过全外显子组测序(即基因组的所有蛋白质编码区)鉴定的罕见(小等位基因频率< 5%)编码变异,我们将检验罕见变异单独和集体导致心肌梗死风险的假设,并进一步证明这种知识可以改善基于人群的风险分层。为了验证这些假设,我们提出以下具体目标:在目标1中,我们将
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nathan Oliver Stitziel其他文献
Nathan Oliver Stitziel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nathan Oliver Stitziel', 18)}}的其他基金
Mechanistic Studies of the Novel Human Coronary Artery Disease Gene SVEP1
人类新型冠状动脉疾病基因SVEP1的机制研究
- 批准号:
10590681 - 财政年份:2022
- 资助金额:
$ 13.72万 - 项目类别:
Mechanistic Studies of the Novel Human Coronary Artery Disease Gene SVEP1
人类新型冠状动脉疾病基因SVEP1的机制研究
- 批准号:
10446520 - 财政年份:2022
- 资助金额:
$ 13.72万 - 项目类别:
Project 2: Regulation of lipid and glucose metabolism by ANGPTL3 in humans
项目2:ANGPTL3对人体脂质和葡萄糖代谢的调节
- 批准号:
10450862 - 财政年份:2020
- 资助金额:
$ 13.72万 - 项目类别:
Project 2: Regulation of lipid and glucose metabolism by ANGPTL3 in humans
项目2:ANGPTL3对人体脂质和葡萄糖代谢的调节
- 批准号:
10642750 - 财政年份:2020
- 资助金额:
$ 13.72万 - 项目类别:
ANGPTL3 DEFICIENCY AND ATHEROSCLEROSIS IN HUMANS
ANGPTL3 缺陷与人类动脉粥样硬化
- 批准号:
9083441 - 财政年份:2016
- 资助金额:
$ 13.72万 - 项目类别:
ANGPTL3 DEFICIENCY AND ATHEROSCLEROSIS IN HUMANS
ANGPTL3 缺陷与人类动脉粥样硬化
- 批准号:
9242062 - 财政年份:2016
- 资助金额:
$ 13.72万 - 项目类别:
Rare coding variation and risk for myocardial infarction
罕见的编码变异和心肌梗塞的风险
- 批准号:
8523197 - 财政年份:2012
- 资助金额:
$ 13.72万 - 项目类别:
Rare coding variation and risk for myocardial infarction
罕见的编码变异和心肌梗塞的风险
- 批准号:
8352120 - 财政年份:2012
- 资助金额:
$ 13.72万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 13.72万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 13.72万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 13.72万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 13.72万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 13.72万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 13.72万 - 项目类别:
Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 13.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 13.72万 - 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 13.72万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 13.72万 - 项目类别:














{{item.name}}会员




